Navigation Links
Northwest Bio Reaffirms Its Freedom to Operate; Refutes Other Parties' Misleading Patent Assertions
Date:12/19/2011

repeatedly over nearly eight years to obtain a broader scope, but the USPTO rejected all of those attempts because multiple other researchers (including Dr. Liau and NW Bio) had already used dendritic cell treatments in a wide variety of sequences and timings with chemotherapies years before the Cedars Sinai/IMUC patent application was filed.  

Simply stated, NW Bio's DCVax product and treatment regimen do not fall within the narrow sequence and timing covered by the '090 patent.  The purpose and focus of NW Bio's clinical trials is to prove that DCVax is an effective treatment on its own.  Moreover, when NW Bio's DCVax reaches commercialization, the treating physician, not NW Bio, will be the party who administers DCVax, and who determines what further treatment to use in the event of recurrence.  NW Bio does not advise on post-recurrence therapies other than the use of its vaccine.  It is the physician who will determine whether to administer chemotherapy and, if so, which type of chemotherapy and in what manner. 

Additionally, all of these treatment activities can be undertaken by the physician free of the '090 patent in a variety of ways.  For example, step (b) of the patent was narrowed following USPTO rejections so as to include only the specific drugs listed. This list does not include the chemotherapy that doctors usually prescribe today after glioma recurrence (Avastin). 

  • The '090 patent is not applicable to treatment for most types of cancer.

Cedars Sinai/IMUC application sought a patent for "treating a disease condition in a mammal" but this was rejected by the USPTO.  Indeed, the USPTO would not even allow coverage of all cancers, or even all cancers of the central nervous system.  The patent claim was narrowed to just "treating a glioma in a mammal."  Glioma is only one of multiple sub-types of one cancer:  pr
'/>"/>

SOURCE Northwest Biotherapeutics
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. Northwestern chemists take gold, mass-produce Beijing Olympic logo
2. Northwest Secures US$1.0 Million Debt Financing
3. Northwest Secures US$1.65 Million Debt Financing
4. Northwest Biotherapeutics Settles Class Action Complaint, and SEC Investigation Closed Without Action
5. Pacific Northwest National Laboratories Becomes a GeneGo Center of Excellence
6. Northwest Biotherapeutics Secures $700,000 Equity Financing
7. Sirius Genomics to Present at Invest Northwest Conference
8. Oncothyreon to present at Invest Northwest 2009
9. Cell Therapeutics, Inc. (CTI) to Present at 8th Annual WBBA Invest Northwest Conference
10. Cell Therapeutics Presents Corporate Highlights at Invest Northwest Conference
11. Dendreon Corporation CEO Mitchell H. Gold, M.D. Named Ernst & Young Entrepreneur of the Year(R) 2009 Award Finalist in the Pacific Northwest
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... TRIANGLE PARK, N.C., USA (PRWEB) May 17, 2013 ...     Green Globes Certified for sustainability , ... and insect pressures , Syngenta ... opening celebration today at the company’s RTP Innovation Center. ... Lab allows company researchers to simulate any agricultural climate ...
(Date:5/17/2013)... 17, 2013 /PRNewswire-iReach/ -- Aridis is pleased to ... Switzerland -based Kenta Biotech to ... antibody (mAb) products, and technologies. This asset portfolio ... treatment of infections by common pathogens including drug ... Pseudomonas aeruginosa , Acinetobacter baumannii ...
(Date:5/17/2013)... Frederick, MD (PRWEB) May 17, 2013 ... release of ezColony version 4.1, a versatile refinement ... world-class premier software solution, improves its advanced methodical ... animal facilities with ezColony 4.1. The network-based platform ... to conduct effective research. While continuing to emphasize ...
(Date:5/16/2013)... (PRWEB) May 16, 2013 The ... by Global Cooling, Inc., Athens, OH, USA, won the ... by the International Society for Biological and Environmental Repositories ... award, given to one product annually, recognizes the company’s ... ultra-low temperature freezer. The award was presented to ...
Breaking Biology Technology:Syngenta Opens Unique $72 Million Advanced Crop Lab 2Syngenta Opens Unique $72 Million Advanced Crop Lab 3Aridis Pharmaceuticals Announces Acquisition of Monoclonal Antibody Products and Technologies From Kenta Biotech 2Aridis Pharmaceuticals Announces Acquisition of Monoclonal Antibody Products and Technologies From Kenta Biotech 3RURO Introduces ezColony 4.1 – The Versatile Transgenic Animal Colony Management Software 2Stirling Ultracold Ultra-Low Freezer Wins 2013 Outstanding New Product Award at International Biorepository Conference, Sydney, Australia 2
... Inhibitor (human)] Commercial Launch --EXTON, Pa., Feb. 24 ViroPharma ... results for the fourth quarter and year ended December 31, ... , ... 2008; , Initiated commercial ...
... DiagnosticsSALT LAKE CITY, Feb. 24 Axial Biotech, ... development of molecular diagnostic technologies, announced today that ... management team as the company,s new Vice President ... directly to Kenneth Ward, M.D., Chairman and Chief ...
... 23 Smith & Nephew, Inc.,(NYSE: SNN ... the,introduction of VISIONAIRE Patient Matched instrumentation for use in ... that,uses a patient,s MRI and x-rays to create custom ... of high performance knee implants. , ...
Cached Biology Technology:ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results 2ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results 3ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results 4ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results 5ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results 6ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results 7ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results 8ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results 9ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results 10ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results 11ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results 12Axial Biotech Appoints Dr. Roberto Macina to Vice President of Research and Development 2Smith & Nephew Launches VISIONAIRE(TM) Patient Matched Technology for Total Knee Replacement 2Smith & Nephew Launches VISIONAIRE(TM) Patient Matched Technology for Total Knee Replacement 3
(Date:5/16/2013)... developed at MIT may someday eliminate the need ... monitor their blood-sugar levels and inject themselves with ... glucose levels in the body and respond by ... the function of pancreatic islet cells, which are ... this type of system could ensure that blood-sugar ...
(Date:5/16/2013)... Philadelphia, PA, May 16, 2013 The relationship ... intelligence (IQ) has not been clear. Schizophrenia is ... functional disability. There are clues that reduced IQ ... schizophrenia. For example, reduced cognitive ability may precede ... may be present in healthy relatives of people ...
(Date:5/16/2013)... S.C. , May 16, 2013 ... in combination with a custom thin film transistor ... highest forensic quality roll image in the smallest ... today. Sherlock, an Appendix F Mobile ID FAP ... a 95% reduction in size and weight when ...
Breaking Biology News(10 mins):Nanotechnology could help fight diabetes 2Nanotechnology could help fight diabetes 3Genetic risk for schizophrenia is connected to reduced IQ 2
... of 35 headwater basins in the United States and Canada ... rates was less than expected in many locations, suggesting that ... change. The study was just published in a special ... Long-Term Ecological Research (LTER) network of 26 sites around the ...
... Notre Dame,s Eck Institute for Global Health developed a ... drug resistance, an effort that will allow for real-time ... The new discovery is described in a paper appearing ... Science . The team of researchers includes Notre ...
... women will be diagnosed with breast cancer during her ... chance of successful treatment and long-term survival. However, early ... remains cumbersome, costly, and in many cases, cancer can ... based in the Dept. of Biomedical Engineering at McGill ...
Cached Biology News:Impact of warming climate doesn't always translate to streamflow 2Notre Dame researchers using novel method to combat malaria drug resistance 2Notre Dame researchers using novel method to combat malaria drug resistance 3Detecting breast cancer's fingerprint in a droplet of blood 2
... SilverQuest Silver Staining Kit is uniquely ... sensitivity with minimal protein modification for ... spectrometry problems associated with traditional silver ... kit because the reagents used do ...
...
... Insect Medium is formuatled for the ... Sf9 and Sf21 cells. Grace's Insect ... because it does not contain lactalbumin ... with transfection. Grace's Insect Medium, Supplemented ...
Schneider's Drosophila Medium is formulated for the expression of heterologous proteins in Drosophila S2 cells....
Biology Products: